Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Eli Lilly and Co. and Purdue University announced Friday that Lilly will invest $250 million in a collaboration between the two over the next eight years. Lilly’s investment is intended to accelerate ...

WSJ Beijing Weighs Fentanyl Offer to U.S. to Start Trade Talks Addressing the Trump team’s gripes over China’s role in the ...

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market ...

We began to recognize initial revenue on our Purdue University contract to provide ... non-GAAP results are calculated by removing the impact of stock-based compensation. We are pleased that ...

One big pharma name stands out as an exceptional opportunity: Bristol Myers Squibb (NYSE: BMY). The stock has been pummeled in 2025, plunging 23% year to date (at the time of this writing ...

For perspective, the S&P 500 trades at approximately 18 times forward earnings, meaning Bristol Myers Squibb stock sells at a ... about sustainability, the pharma titan has successfully navigated ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

2025. Price Action: REGN stock is down 6.38% to $571.90 at the last check Tuesday.